Use of decentralized approach in a Phase 1 pharmacokinetic trial shows the ability to enable remote data collection and ...

Segal Trials, a privately held clinical research network specializing in acute schizophrenia and other psychiatric disorders, ...

Previously, clinical research findings on cadonilimab in the treatment of various malignancies have been published in internationally renowned journals such as The Lancet, The Lancet Oncology, Nature ...

Collaboration to take Cytovation’s synthetic peptide, CY-101, into a Phase 2 trial for patients with adrenocortical carcinomaCancer Research UK’s Centre for Drug Development to run the trial at sites ...

After a Stage 4 cancer diagnosis and a prognosis of 16 months to live, Katie Doble didn’t know whether she should plan her ...

Valneva’s vaccine was highly immunogenic in both dose groups. A full dose of the vaccine exhibited a more robust immune response compared to a half dose by providing protective antibody titers already ...

Cebranopadol is an investigational dual-nociceptin/orphanin FQ peptide receptor and µ-opioid peptide receptor agonist.

NDAQ:ZLAB) Zai Lab Receives Orphan Drug Designation from the U.S. FDA for ZL-1310 (DLL3 ADC) for the Treatment of Small Cell ...

Biodexa Strengthens Management Team Appointment of Dr Gary A. Shangold as Chief Medical Officer Biodexa Pharmaceuticals PLC ("Biodexa" or "the Company"), (Nasdaq: BDRX), a clinical ...

Celldex Therapeutics , Inc. (NASDAQ:CLDX), a biopharmaceutical company with a market capitalization of $1.6 billion focused on developing innovative therapies for challenging diseases, has been making ...

Finally, Protagonist Therapeutics (NASDAQ:PTGX) has indicated that its financial runway extends beyond the fourth quarter of 2028, providing the company with a stable foundation to continue its ...